vs
Side-by-side financial comparison of Bolt Biotherapeutics, Inc. (BOLT) and KOSS CORP (KOSS). Click either name above to swap in a different company.
KOSS CORP is the larger business by last-quarter revenue ($2.9M vs $2.5M, roughly 1.1× Bolt Biotherapeutics, Inc.). KOSS CORP runs the higher net margin — -19.8% vs -265.2%, a 245.5% gap on every dollar of revenue. Over the past eight quarters, KOSS CORP's revenue compounded faster (4.2% CAGR vs -31.2%).
Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company specializing in immune-stimulating antibody conjugate (ISAC) therapies for cancer treatment. Its core pipeline targets hard-to-treat solid tumors, serving global oncology markets and advancing novel immunotherapies that trigger targeted anti-tumor immune responses to improve patient outcomes.
Koss Corporation is a company in Milwaukee, Wisconsin, US that manufactures headphones. The company created the first high-fidelity stereo headphones in 1958.
BOLT vs KOSS — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $2.5M | $2.9M |
| Net Profit | $-6.6M | $-565.4K |
| Gross Margin | — | 29.0% |
| Operating Margin | -283.4% | -35.5% |
| Net Margin | -265.2% | -19.8% |
| Revenue YoY | — | -19.6% |
| Net Profit YoY | 58.4% | -700.6% |
| EPS (diluted) | $-9.38 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.5M | $2.9M | ||
| Q3 25 | $2.2M | $4.1M | ||
| Q2 25 | $1.8M | $3.1M | ||
| Q1 25 | $1.2M | $2.8M | ||
| Q4 24 | $0 | $3.6M | ||
| Q3 24 | $1.1M | $3.2M | ||
| Q2 24 | $1.3M | $2.9M | ||
| Q1 24 | $5.3M | $2.6M |
| Q4 25 | $-6.6M | $-565.4K | ||
| Q3 25 | $-7.1M | $243.7K | ||
| Q2 25 | $-8.6M | $-232.7K | ||
| Q1 25 | $-11.0M | $-316.7K | ||
| Q4 24 | $-15.9M | $94.1K | ||
| Q3 24 | $-15.2M | $-419.5K | ||
| Q2 24 | $-21.2M | $-110.4K | ||
| Q1 24 | $-10.8M | $-313.8K |
| Q4 25 | — | 29.0% | ||
| Q3 25 | — | 40.0% | ||
| Q2 25 | — | 36.0% | ||
| Q1 25 | — | 39.0% | ||
| Q4 24 | — | 39.5% | ||
| Q3 24 | — | 36.6% | ||
| Q2 24 | — | 40.4% | ||
| Q1 24 | — | 31.9% |
| Q4 25 | -283.4% | -35.5% | ||
| Q3 25 | -355.1% | -1.1% | ||
| Q2 25 | -510.5% | -14.2% | ||
| Q1 25 | -991.4% | -18.7% | ||
| Q4 24 | — | -4.0% | ||
| Q3 24 | -1441.1% | -19.9% | ||
| Q2 24 | -1772.3% | -11.0% | ||
| Q1 24 | -324.1% | -23.1% |
| Q4 25 | -265.2% | -19.8% | ||
| Q3 25 | -329.4% | 6.0% | ||
| Q2 25 | -474.6% | -7.5% | ||
| Q1 25 | -903.4% | -11.4% | ||
| Q4 24 | — | 2.6% | ||
| Q3 24 | -1330.1% | -13.1% | ||
| Q2 24 | -1662.4% | -3.8% | ||
| Q1 24 | -205.0% | -11.9% |
| Q4 25 | $-9.38 | $-0.06 | ||
| Q3 25 | $-3.72 | $0.03 | ||
| Q2 25 | $-4.46 | $-0.02 | ||
| Q1 25 | $-0.29 | $-0.03 | ||
| Q4 24 | $-13.73 | $0.01 | ||
| Q3 24 | $-7.93 | $-0.05 | ||
| Q2 24 | $-11.12 | $-0.01 | ||
| Q1 24 | $-0.28 | $-0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $27.5M | $15.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $26.5M | $30.3M |
| Total Assets | $56.7M | $36.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.5M | $15.5M | ||
| Q3 25 | $31.9M | $16.5M | ||
| Q2 25 | $34.8M | $15.7M | ||
| Q1 25 | $38.8M | $13.0M | ||
| Q4 24 | $47.3M | $9.7M | ||
| Q3 24 | $53.8M | $11.9M | ||
| Q2 24 | $73.7M | $14.9M | ||
| Q1 24 | $91.3M | $9.9M |
| Q4 25 | $26.5M | $30.3M | ||
| Q3 25 | $32.1M | $30.9M | ||
| Q2 25 | $38.8M | $30.6M | ||
| Q1 25 | $46.8M | $30.7M | ||
| Q4 24 | $57.2M | $31.0M | ||
| Q3 24 | $72.0M | $30.8M | ||
| Q2 24 | $85.9M | $31.1M | ||
| Q1 24 | $104.2M | $31.1M |
| Q4 25 | $56.7M | $36.8M | ||
| Q3 25 | $65.1M | $37.7M | ||
| Q2 25 | $75.5M | $37.2M | ||
| Q1 25 | $85.9M | $37.3M | ||
| Q4 24 | $99.6M | $37.4M | ||
| Q3 24 | $109.3M | $38.1M | ||
| Q2 24 | $124.2M | $37.2M | ||
| Q1 24 | $142.9M | $37.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-7.2M | $-760.8K |
| Free Cash FlowOCF − Capex | — | $-1.1M |
| FCF MarginFCF / Revenue | — | -37.5% |
| Capex IntensityCapex / Revenue | — | 10.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-546.7K |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-7.2M | $-760.8K | ||
| Q3 25 | $-9.7M | $762.6K | ||
| Q2 25 | $-9.6M | $-534.9K | ||
| Q1 25 | $-13.4M | $370.4K | ||
| Q4 24 | $-14.4M | $-252.0K | ||
| Q3 24 | $-14.0M | $201.6K | ||
| Q2 24 | $-16.1M | $-174.0K | ||
| Q1 24 | $-16.8M | $328.6K |
| Q4 25 | — | $-1.1M | ||
| Q3 25 | — | $761.5K | ||
| Q2 25 | — | $-541.8K | ||
| Q1 25 | — | $306.2K | ||
| Q4 24 | — | $-314.3K | ||
| Q3 24 | $-14.0M | $-155.6K | ||
| Q2 24 | — | $-174.8K | ||
| Q1 24 | — | $269.3K |
| Q4 25 | — | -37.5% | ||
| Q3 25 | — | 18.7% | ||
| Q2 25 | — | -17.6% | ||
| Q1 25 | — | 11.0% | ||
| Q4 24 | — | -8.8% | ||
| Q3 24 | -1227.6% | -4.9% | ||
| Q2 24 | — | -6.0% | ||
| Q1 24 | — | 10.2% |
| Q4 25 | — | 10.9% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.2% | ||
| Q1 25 | — | 2.3% | ||
| Q4 24 | — | 1.8% | ||
| Q3 24 | 3.6% | 11.2% | ||
| Q2 24 | 0.0% | 0.0% | ||
| Q1 24 | 0.0% | 2.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | 3.13× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -2.68× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
